Quick Answer
Cordyceps Sunshine Biotech Holdings Co., Ltd. reported Cash and Equivalents of $37.3 thousand for fiscal year 2024.
Cordyceps Sunshine Biotech Holdings Co., Ltd. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $37.3K | +61.4% |
| 2023 | $23.1K | +248.6% |
| 2022 | $6.6K | -93.4% |
| 2021 | $99.7K | +33806.1% |
| 2020 | $294.00 | — |
- Cordyceps Sunshine Biotech Holdings Co., Ltd. showed an increase of +61.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2024 period, Cordyceps Sunshine Biotech Holdings Co., Ltd.’s cash and equivalents has grown by 12581.6% (from $294.00 to $37.3 thousand).
- The most recent figure is from Cordyceps Sunshine Biotech Holdings Co., Ltd.’s fiscal year 2024 report (Form 20-F), filed with the SEC on June 13, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: